Iovance Biotherapeutics, Inc. (IOVA)
14.22
-0.02
(-0.11%)
USD |
NASDAQ |
Oct 02, 16:00
14.22
+0.01
(+0.07%)
After-Hours: 20:00
Iovance Biotherapeutics Enterprise Value : 6.187B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 6.187B |
| October 01, 2026 | 6.194B |
| September 30, 2026 | 6.461B |
| September 29, 2026 | 6.294B |
| September 28, 2026 | 4.726B |
| September 25, 2026 | 4.731B |
| September 24, 2026 | 4.640B |
| September 23, 2026 | 4.364B |
| September 22, 2026 | 4.568B |
| September 21, 2026 | 4.364B |
| September 18, 2026 | 4.391B |
| September 17, 2026 | 4.287B |
| September 16, 2026 | 4.219B |
| September 15, 2026 | 3.988B |
| September 14, 2026 | 3.943B |
| September 11, 2026 | 3.644B |
| September 10, 2026 | 3.436B |
| September 09, 2026 | 3.567B |
| September 08, 2026 | 3.689B |
| September 04, 2026 | 3.730B |
| September 03, 2026 | 3.689B |
| September 02, 2026 | 3.653B |
| September 01, 2026 | 3.499B |
| August 31, 2026 | 3.449B |
| August 28, 2026 | 3.377B |
| Date | Value |
|---|---|
| August 27, 2026 | 3.490B |
| August 26, 2026 | 3.408B |
| August 25, 2026 | 3.571B |
| August 24, 2026 | 3.399B |
| August 21, 2026 | 3.503B |
| August 20, 2026 | 3.821B |
| August 19, 2026 | 3.368B |
| August 18, 2026 | 2.933B |
| August 17, 2026 | 2.964B |
| August 14, 2026 | 2.910B |
| August 13, 2026 | 2.702B |
| August 12, 2026 | 2.801B |
| August 11, 2026 | 2.688B |
| August 10, 2026 | 2.647B |
| August 07, 2026 | 2.620B |
| August 06, 2026 | 2.561B |
| August 05, 2026 | 1.714B |
| August 04, 2026 | 1.723B |
| August 03, 2026 | 1.703B |
| July 31, 2026 | 1.592B |
| July 30, 2026 | 1.873B |
| July 29, 2026 | 1.814B |
| July 28, 2026 | 1.877B |
| July 27, 2026 | 1.968B |
| July 24, 2026 | 2.009B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AVITA Medical, Inc. | 430.73M |
| Amgen, Inc. | 261.20B |
| Halozyme Therapeutics, Inc. | 14.44B |
| Neurocrine Biosciences, Inc. | 14.56B |
| Editas Medicine, Inc. | 261.86M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -47.32M |
| Revenue (Quarterly) | 99.31M |
| Total Expenses (Quarterly) | 146.63M |
| EPS Diluted (Quarterly) | -0.1051 |
| Gross Profit Margin (Quarterly) | 46.54% |
| Profit Margin (Quarterly) | -47.64% |
| Earnings Yield | -5.07% |
| Normalized Earnings Yield | -5.005 |